Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial

Key Points

• Truist Financial raised Regeneron’s price target from $772 to $780 and maintained a “buy” rating, implying 4.8% upside from the prior close.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average target price of $814.88; JPMorgan and Guggenheim also recently increased their targets.
• Regeneron’s latest quarterly results exceeded expectations, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective increased by Truist Financial from $772.00 to $780.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Truist Financial's target price suggests a potential upside of 4.80% from the stock's previous close.

Several other analysts also recently weighed in on REGN. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a research report on Tuesday. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, September 28th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research report on Thursday, July 9th. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $814.88.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of REGN traded up $5.57 during trading hours on Wednesday, hitting $744.28. The company had a trading volume of 265,238 shares, compared to its average volume of 825,812. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average price is $790.36 and its 200 day moving average price is $720.41. The firm has a market cap of $76.63 billion, a P/E ratio of 18.40, a P/E/G ratio of 1.39 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the business posted $12.81 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals will post 45.37 EPS for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the company's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock valued at $3,302,458 over the last quarter. 6.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $29,000. Finally, Fiduciary Financial Advisors bought a new position in Regeneron Pharmaceuticals in the second quarter worth $29,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and maintained an “overweight” rating, implying substantial upside from the referenced share price. The move reflects a more bullish view of Regeneron’s earnings potential and drug pipeline.
• Positive Sentiment: Regeneron expanded its long-running antibody alliance with Sanofi, receiving $1 billion upfront and becoming eligible for as much as $7 billion in additional milestone payments. The deal adds non-dilutive funding and validates Regeneron’s next-generation antibody programs. Expanded Sanofi Alliance and New Pipeline Data Could Be a Game Changer for Regeneron
• Positive Sentiment: New oncology data presented at ESMO 2026 strengthened the investment case for Libtayo (cemiplimab). Longer-term Phase 3 C-POST results showed survival outcomes in high-risk cutaneous squamous cell carcinoma, while additional studies evaluated pre-surgery treatment and Factor XI inhibition for cancer-associated thrombosis. Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
• Positive Sentiment: Morgan Stanley lifted its price target from $758 to $779, indicating modest additional upside and acknowledging improved valuation or business expectations.
• Neutral Sentiment: Morgan Stanley retained an “equal weight” rating, signaling that it views REGN as fairly valued relative to peers despite the higher target.
• Neutral Sentiment: Analyst opinions remain mixed across recent healthcare research. The conflicting ratings suggest investors may continue to debate Regeneron’s valuation, pipeline execution and longer-term growth prospects. Analysts Conflicted on These Healthcare Names

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.